champc/iStock via Getty Images Sage Therapeutics ( NASDAQ: SAGE ) traded sharply higher premarket Tuesday after announcing that its Phase 2 SURVEYOR study for its experimental therapy dalzanemdor (SAGE-718) reached the main goal in patients with a rare disorder called Huntington's disease (HD). According to the company, the 40-subject trial "met its primary endpoint, demonstrating a statistically significant difference" in relation to a clinical measure known as the HD-Cognitive Assessment Battery (HD-CAB) as measured between healthy participants and patients. However, the Cambridge, Massachusetts-based biotech added that the trial was not powered to measure a statistically significant difference between those who received dalzanemdor and those on placebo.
Sage ( SAGE ) noted that there were no new safety signals, and the study drug was well tolerated among trial participants. 11 patients suffered from treatment-emergent adverse events, but there were no TEAE-related discontinuations. The company said it would use SURVEYOR findings in its LIGHTWAVE and DIMENSION studies for dalzanemdor in Alzheimer's disease and HD-related cognitive impairment, respectively.
Topline data from the latter trials are expected later this year. More on Sage Therapeutics Sage Therapeutics Stock: Remains A Hold On Upcoming Essential Tremor Treatment Data Sage Therapeutics, Inc.(SAGE) Q1 2024 Earnings Call Transcript Sage Therapeutics, Inc.
2024 Q1 - Results - Earnings Call Presentation Sage Therapeu.
